Chemically modified haemoglobin solutions represent a potential altern
ative to the transfusion of donor blood. The theoretical advantages of
these products include an oxygen delivery potential greater than that
of conventional plasma expanders, prolonged shelf-life, universal com
patibility and the absence of pathogenic viruses. Principal concerns h
ave been safety issues including renal toxicity, coagulopathy and vaso
activity, The proposed indications for these solutions are primarily r
esuscitation of patients in haemorrhagic shock and porioperative haemo
dilution during elective surgery. Three products have now undergone ph
ase I safety trials in human subjects and phase II safety and efficacy
trials are planned in the near future.